HK1087351A1 - Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit - Google Patents

Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Info

Publication number
HK1087351A1
HK1087351A1 HK06109214.5A HK06109214A HK1087351A1 HK 1087351 A1 HK1087351 A1 HK 1087351A1 HK 06109214 A HK06109214 A HK 06109214A HK 1087351 A1 HK1087351 A1 HK 1087351A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
phosphodiesesterase
treatment
cognitive deficit
cognitive
Prior art date
Application number
HK06109214.5A
Other languages
English (en)
Inventor
Timothy P Tully
Filippo Cavalieri
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Publication of HK1087351A1 publication Critical patent/HK1087351A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Insulating Materials (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Magnetic Ceramics (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
HK06109214.5A 2003-04-08 2006-08-21 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit HK1087351A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/410,508 US20040224316A1 (en) 2000-08-10 2003-04-08 Augmented cognitive training
PCT/US2004/010876 WO2004091609A2 (en) 2001-08-10 2004-04-08 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Publications (1)

Publication Number Publication Date
HK1087351A1 true HK1087351A1 (en) 2006-10-13

Family

ID=37416211

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12100142.3A HK1159514A1 (en) 2003-04-08 2006-08-21 Ht0712 for the treatment of a cognitive deficit ht0712
HK06109214.5A HK1087351A1 (en) 2003-04-08 2006-08-21 Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK12100142.3A HK1159514A1 (en) 2003-04-08 2006-08-21 Ht0712 for the treatment of a cognitive deficit ht0712

Country Status (8)

Country Link
US (2) US20040224316A1 (es)
EP (4) EP1631281B1 (es)
JP (1) JP4833834B2 (es)
AT (1) ATE556707T1 (es)
CA (1) CA2521839C (es)
ES (3) ES2403283T3 (es)
HK (2) HK1159514A1 (es)
WO (1) WO2004091609A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8975216B2 (en) * 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
JP2009537568A (ja) * 2006-05-19 2009-10-29 ヘリコン セラピューティクス，インコーポレイテッド 認知および運動のリハビリテーションのためのホスホジエステラーゼ４インヒビター
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds
US20100168170A1 (en) * 2007-03-12 2010-07-01 Benjamin Pelcman Piperidinones Useful in the Treatment of Inflammation
BRPI0811623A2 (pt) * 2007-05-15 2014-11-11 Helicon Therapeutics Inc Métodos para identificar genes envolvidos na formação de memória usando pequeno rna interferente (sirna)
US7968524B2 (en) * 2007-05-15 2011-06-28 Helicon Therapeutics, Inc. Methods of enhancing long term memory formation by inhibition of Gpr12
JP5049713B2 (ja) * 2007-09-14 2012-10-17 株式会社コナミデジタルエンタテインメント ゲームシステム並びにこれを構成するゲーム装置及び課題報知装置
KR20110049801A (ko) * 2008-07-18 2011-05-12 다트 뉴로사이언시즈, 엘엘씨 기억 물질의 평가를 위한 방법 및 시스템
WO2011114103A1 (en) 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
US20150050626A1 (en) * 2013-03-15 2015-02-19 Dart Neuroscience, Llc Systems, Methods, and Software for Improving Cognitive and Motor Abilities
WO2015144598A1 (en) * 2014-03-28 2015-10-01 Algiax Pharmaceuticals Gmbh Treatment of cognitive disorders
WO2022156727A1 (zh) 2021-01-21 2022-07-28 浙江养生堂天然药物研究所有限公司 治疗肿瘤的组合物及方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5479508A (en) * 1991-05-22 1995-12-26 Zenith Electronics Corp. Method of operating a pay per view television system
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
WO1993021347A1 (en) 1992-04-10 1993-10-28 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
US5817670A (en) * 1994-08-29 1998-10-06 Yamanouchi Pharmaceutical Co., Ltd. Naphthyridine derivatives and pharmaceutical compositions thereof
US5619249A (en) * 1994-09-14 1997-04-08 Time Warner Entertainment Company, L.P. Telecasting service for providing video programs on demand with an interactive interface for facilitating viewer selection of video programs
US5929223A (en) * 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
CA2202087C (en) 1994-10-07 2011-12-06 Timothy P. Tully Cloning and characterizing of genes associated with long-term memory
US5652749A (en) * 1995-02-03 1997-07-29 International Business Machines Corporation Apparatus and method for segmentation and time synchronization of the transmission of a multiple program multimedia data stream
US5793410A (en) * 1995-05-26 1998-08-11 Hyundai Electronics America Video pedestal network
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
CA2276455C (en) * 1997-01-15 2006-10-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinones
JP4979157B2 (ja) 1998-09-09 2012-07-18 バイオリポックス アーべー 置換されたγ−フェニル−Δ−ラクトンおよびそのアナログならびにこれらに関する使用
IT1303272B1 (it) 1998-10-29 2000-11-06 Zambon Spa Derivati triciclici inibitori della fosfodiesterasi 4
CA2364653A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
US7947731B2 (en) * 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
AU2003258287A1 (en) * 2002-08-19 2004-03-03 Helicon Therapeutics, Inc. Screening methods for cognitive enhancers

Also Published As

Publication number Publication date
ES2403333T3 (es) 2013-05-17
JP2006524243A (ja) 2006-10-26
ATE556707T1 (de) 2012-05-15
JP4833834B2 (ja) 2011-12-07
EP2116240B1 (en) 2013-02-27
WO2004091609A3 (en) 2007-08-16
CA2521839C (en) 2014-08-05
EP1631281B1 (en) 2012-05-09
EP2340831B1 (en) 2014-09-10
WO2004091609A2 (en) 2004-10-28
EP2116240A1 (en) 2009-11-11
HK1159514A1 (en) 2012-08-03
EP1631281A2 (en) 2006-03-08
CA2521839A1 (en) 2004-10-28
EP2340831A1 (en) 2011-07-06
EP2156831B1 (en) 2013-02-27
ES2509093T3 (es) 2014-10-17
ES2403283T3 (es) 2013-05-17
US8097647B2 (en) 2012-01-17
US20040224316A1 (en) 2004-11-11
US20060247252A1 (en) 2006-11-02
EP2156831A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
HK1087351A1 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
WO2005048948A3 (en) Urea derivatives as kinase modulators
PL1765388T3 (pl) Terapia skojarzona do zapobiegania chorobie Alzheimera lub leczenia tej choroby oraz zestaw do tego celu
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
EP1581629A4 (en) METHODS FOR IDENTIFYING, EVALUATING AND TREATING PATIENTS FOLLOWING PROTEASOME INHIBITION THERAPY
PT1687284E (pt) Inibidores de quinase p-38
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
EP1535971A4 (en) TREATED PIGMENT, ITS USE, AND COMPOUND FOR THE TREATMENT OF PIGMENTS
SG155912A1 (en) B-cell reduction using cd37-specific and cd20-specific binding molecules
EP1809369A4 (en) MEDICAL DEVICES FOR DETECTION, PREVENTION AND / OR TREATMENT OF NEUROLOGICAL DISEASES AND RELEVANT PROCEDURES
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
DK1355669T3 (da) Forbedret kognitiv træning
MY130489A (en) Substituted aryl 1, 4-pyrazine derivatives
WO2007028151A3 (en) Surgical devices and related methods thereof
DK1408976T5 (da) Behandling af ADHD (Attention deficit hyperactivity disorder)
BRPI0417108A (pt) métodos de tratamento de rejeições de transplantes em pacientes
HK1080408A1 (en) Use of brimonidine in the treatment of dementia a nd parkinson
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
MXPA05002418A (es) Derivados de 1,4-pirazina sustituidos.
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
GB2388027B (en) Use of palatinose for the treatment of mental stress
EP1601799A4 (en) METHODS AND COMPOSITIONS FOR TREATING AIDS AND HIV-ASSOCIATED DISEASES USING 9145, 1725, 311, 837, 58305, 156, 14175, 50352, 32678, 5560, 7240, 8865, 12396, 12397, 13644, 19938, 2077, 1735 , 1786, 10220, 17822, 33945, 43748, 47161, 81982, OR 46777
WO2005009354A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
WO2003092478A3 (en) Methods for treating neuronal disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180408